GlassScriptPhysician profile
Warren W Chin
NPI 1700988060
$202,823.36
in general payments reported to CMS, 2019-2025
19 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $24K · 2021: $21K · 2022: $40K · 2023: $21K · 2024: $20K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $5,814 · Food and Beverage: $4,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,505.00 |
| Travel and Lodging | $5,814.05 |
| Food and Beverage | $4,026.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $102,561.31 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $73,826.07 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $19,118.54 | 2019-2025 | Jardiance |
| Pfizer INC. | $2,775.83 | 2019 | |
| Boston Scientific Corporation | $1,118.51 | 2019-2025 | Watchman, Watchman Access System, Zoom Wireless Transmitter |
| Medtronic Vascular, INC. | $585.97 | 2019-2020 | |
| Esperion Therapeutics, INC. | $470.77 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $374.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $373.54 | 2019 | |
| Abbvie INC. | $326.91 | 2022-2023 | Vraylar |
| Biotronik INC. | $301.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $211.65 | 2019 | |
| Amarin Pharma, INC. | $198.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $185.52 | 2019-2024 | Camzyos, Eliquis |
| Alexion Pharmaceuticals, INC. | $135.46 | 2024 | Strensiq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $133.41 | 2019 | |
| Abbott Laboratories | $77.78 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $35.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.